ALBIREO PHARMA, INC. Contracts & Agreements

Agreement and Plan of Merger, dated as of January 8, 2023, by and among Ipsen Biopharmaceuticals, Inc., Anemone Acquisition Corp., Albireo Pharma, Inc. and, solely for the limited... (Filed With SEC on January 9, 2023)

Purchase and Sale Agreement, dated as of September 22, 2022, by and among the Registrant, Albireo AB and Sagard Healthcare Partners (Delaware) LP (Filed With SEC on November 8, 2022)

Nonemployee Director Compensation Policy, as amended (Filed With SEC on August 10, 2022)

Description of the Registrants Securities (Filed With SEC on March 1, 2022)

Amendment No. 3 to Office Lease Agreement, dated as of June 30, 2021, by and between NS Boston III PO Owner LLC and the Registrant (Filed With SEC on March 1, 2022)

Sublease Agreement, dated as of December 6, 2021, by and between the Registrant and Hi Marley, Inc (Filed With SEC on March 1, 2022)

Sublease Agreement, dated as of December 7, 2021, by and between the Registrant Institute For Healthcare Improvement (Filed With SEC on March 1, 2022)

Asset Purchase Agreement, dated as of August 31, 2021, by and among the Registrant, Albireo AB and Ares Trading SA (Filed With SEC on November 4, 2021)

Albireo Pharma, Inc. Incentive Compensation Recoupment Policy (Filed With SEC on November 4, 2021)

Albireo Pharma, Inc. 2018 Equity Incentive Plan, as amended (Filed With SEC on June 21, 2021)

Nonemployee Director Compensation Policy (Filed With SEC on May 6, 2021)

Sales Agreement, dated February 25, 2021, by and between Albireo Pharma, Inc. and Cowen and Company, LLC (Filed With SEC on February 25, 2021)

Albireo Pharma, Inc. 2020 Inducement Equity Incentive Plan (Filed With SEC on November 5, 2020)

Form of Stock Option Agreement under the Albireo Pharma, Inc. 2020 Inducement Equity Incentive Plan (Filed With SEC on November 5, 2020)

Form of Restricted Stock Unit Agreement under the Albireo Pharma, Inc. 2020 Inducement Equity Incentive Plan (Filed With SEC on November 5, 2020)

Underwriting Agreement, dated September 9, 2020, by and among the Company, Cowen and Company, LLC and William Blair & Company, L.L.C (Filed With SEC on September 10, 2020)

Loan and Security Agreement, dated as of June 8, 2020, by and between the Company and Hercules Capital, Inc (Filed With SEC on June 9, 2020)

Form of Warrant issued by the Company to Hercules Capital, Inc (Filed With SEC on June 9, 2020)

Amendment No 1. to Royalty Interest Acquisition Agreement, dated as of June 8, 2020, by and among Elobix AB, HealthCare Royalty Partners III, L.P. and, solely for the purposes... (Filed With SEC on June 9, 2020)

Nonemployee Director Compensation Policy (Filed With SEC on May 7, 2020)

Second amendment to Lease dated as of May 4, 2020, by and between NS Boston III PO Owner LLC and the Registrant (Filed With SEC on May 7, 2020)

Description of the Registrants Securities (Filed With SEC on March 2, 2020)

Underwriting Agreement, dated January 29, 2020, by and between the Company and Jefferies LLC (Filed With SEC on January 30, 2020)

Employment Agreement dated as of October 31, 2019 by and between the Registrant and Michelle Graham (Filed With SEC on November 6, 2019)

Albireo Pharma, Inc. 2018 Equity Incentive Plan, as amended (Filed With SEC on June 18, 2019)

Employment Agreement dated as of March 25, 2019 by and between the Registrant and Pamela Stephenson (Filed With SEC on May 9, 2019)

Non-Employee Director Compensation Policy (Filed With SEC on May 9, 2019)

Amendment No. 1 to Office Lease Agreement dated as of March 28, 2019, by and between Albireo Pharma, Inc. and POSIG Investors, LLC (Filed With SEC on April 3, 2019)

Amended and Restated Employment Agreement, dated as of March 6, 2019, by and between the Registrant and Ronald H.W. Cooper (Filed With SEC on March 6, 2019)

Amended and Restated Employment Agreement, dated as of March 6, 2019, by and between Albireo, AB and Jan P. Mattsson, Ph.D (Filed With SEC on March 6, 2019)

Amended and Restated Employment Agreement, dated as of March 6, 2019, by and between the Registrant and Martha J. Carter (Filed With SEC on March 6, 2019)

Amended and Restated Employment Agreement, dated as of March 6, 2019, by and between the Registrant and Patrick Horn (Filed With SEC on March 6, 2019)

Amended and Restated Employment Agreement, dated as of March 6, 2019, by and between Albireo, Inc. and Jason G. Duncan (Filed With SEC on March 6, 2019)

Employment Agreement dated as of July 23, 2018 by and between the Registrant and Patrick T. Horn, M.D., Ph.D (Filed With SEC on November 8, 2018)

Separation Agreement effective as of July 31, 2018 by and between the Registrant and Paresh N. Soni, M.D., Ph.D (Filed With SEC on November 8, 2018)

Employment Agreement dated as of October 4, 2018 by and between the Registrant and Simon N.R. Harford (Filed With SEC on November 8, 2018)

Separation Agreement dated as of October 4, 2018 by and between the Registrant and Thomas A. Shea (Filed With SEC on November 8, 2018)

Inducement Stock Option Agreement dated as of October 10, 2018 by and between the Registrant and Simon N.R. Harford (Filed With SEC on November 8, 2018)

Inducement Restricted Stock Unit Agreement dated as of October 10, 2018 by and between the Registrant and Simon N.R. Harford (Filed With SEC on November 8, 2018)

2018 Equity Incentive Plan (Filed With SEC on August 9, 2018)

Form of Stock Option Agreement under the 2018 Equity Incentive Plan (Filed With SEC on August 9, 2018)

2018 Employee Stock Purchase Plan (Filed With SEC on August 9, 2018)

Employment Agreement dated as of May 16, 2018 by and between the Registrant and Jason G. Duncan (Filed With SEC on August 9, 2018)

Form of Restricted Stock Unit Agreement (Filed With SEC on August 9, 2018)

Form of Stock Option Agreement under the Albireo Pharma, Inc. 2017 Inducement Equity Incentive Plan (Filed With SEC on March 27, 2018)

Nonemployee Director Compensation Policy (Filed With SEC on March 27, 2018)

Third Amendment to the License Agreement, dated as of December 7, 2017, by and between Elobix AB and EA Pharma Co., Ltd. (formerly known as Ajinomoto Pharmaceuticals Co., Ltd.) (Filed With SEC on March 27, 2018)

Royalty Interest Acquisition Agreement, dated as of December 28, 2017, by and among Elobix AB, HealthCare Royalty Partners III, L.P. and, solely for the purposes specified... (Filed With SEC on March 27, 2018)

Underwriting Agreement, dated January 25, 2018, by and among the Company, Cowen and Company, LLC and William Blair & Company, L.L.C (Filed With SEC on January 25, 2018)

Albireo Pharma, Inc. 2017 Inducement Equity Incentive Plan (Filed With SEC on November 14, 2017)

Sales Agreement dated October 13, 2017 by and between Albireo Pharma, Inc. and Cowen and Company, LLC (Filed With SEC on October 13, 2017)

2,200,000 SHARES ALBIREO PHARMA, INC. COMMON STOCK UNDERWRITING AGREEMENT (Filed With SEC on May 24, 2017)

Albireo Pharma, Inc. Nonemployee Director Compensation Policy dated January 23, 2017 (Filed With SEC on May 11, 2017)

LICENSE agreement by and between ALBIREO AB and AJINOMOTO PHARMACEUTICALS CO., LTD. April 2, 2012 (Filed With SEC on March 27, 2017)

FIRST AMENDMENT TO THE LICENSE AGREEMENT (Filed With SEC on March 27, 2017)

SECOND AMENDMENT TO THE LICENSE AGREEMENT (Filed With SEC on March 27, 2017)

ALBIREO PHARMA, INC. NUMBER ALB SHARES (Filed With SEC on December 22, 2016)

EMPLOYMENT AGREEMENT (Filed With SEC on December 22, 2016)

GENERAL RELEASE & WAIVER (Filed With SEC on December 22, 2016)

ALBIREO PHARMA, INC. Stock Option Grant Notice Stock Option Grant under the Companys 2016 Equity Incentive Plan (Filed With SEC on December 22, 2016)

ALBIREO PHARMA, INC. Warrant To Purchase Common Stock (Filed With SEC on November 4, 2016)

(1) KREOS CAPITAL IV (UK) LIMITED (2) ALBIREO LIMITED (3) ALBIREO AB (4) ELOBIX AB SUPPLEMENTALDEED relating to a Loan Agreement dated 18 December 2014 5 Fleet PlaceLondon EC4M... (Filed With SEC on November 4, 2016)

GUARANTY AND SECURITY AGREEMENT (Filed With SEC on November 4, 2016)

EMPLOYMENT AGREEMENT (Filed With SEC on November 4, 2016)

ALBIREO AB AND Jan Mattsson EMPLOYMENT AGREEMENT (Filed With SEC on November 4, 2016)

EMPLOYMENT AGREEMENT (Filed With SEC on November 4, 2016)

FORM OF INDEMNIFICATION AGREEMENT (Filed With SEC on November 4, 2016)

ALBIREO PHARMA, INC. 2016 EQUITY INCENTIVE PLAN (Filed With SEC on November 4, 2016)

ASSETPURCHASE AND LICENSE AGREEMENT (Filed With SEC on September 9, 2016)

AMENDED AND RESTATED SHARE EXCHANGE AGREEMENT BY AND AMONG BIODELINC., ALBIREO LIMITED AND THE SELLERS LISTEDON SCHEDULE I HERETO Dated as of July 13, 2016 (Filed With SEC on July 13, 2016)

SHARE EXCHANGE AGREEMENT (Filed With SEC on May 26, 2016)

[Form of Company Lock-up Agreement] (Filed With SEC on May 26, 2016)

GENERAL RELEASE & WAIVER (Filed With SEC on May 10, 2016)

BIODEL INC. EXECUTIVE EMPLOYMENT AGREEMENT GARY G. GEMIGNANI AMENDMENT (Filed With SEC on April 1, 2016)

BIODEL INC. EXECUTIVE SEVERANCE AGREEMENT AND CHANGE OF CONTROL AGREEMENT PAUL S. BAVIER AMENDMENT (Filed With SEC on April 1, 2016)

BIODEL INC. Common Stock, par value $0.01 per share Underwriting Agreement (Filed With SEC on April 15, 2015)

BIODEL INC. Common Stock, par value $0.01 per share Underwriting Agreement (Filed With SEC on April 2, 2015)

BIODEL INC. EXECUTIVE EMPLOYMENT AGREEMENT (Filed With SEC on August 27, 2014)

PURCHASE AGREEMENT (Filed With SEC on July 28, 2014)

REGISTRATION RIGHTS AGREEMENT (Filed With SEC on July 28, 2014)

OPTION TO RENEW DATED AS OF NOVEMBER 6, 2013 TO LEASE AGREEMENT DATED AS OF JULY 23, 2007 (Filed With SEC on December 20, 2013)

Exhibit 10.23 BASE SALARIES OF NAMED EXECUTIVE OFFICERS OF THE REGISTRANT The following are the base salaries (on an annual basis) of the named executive officers of theCompany:... (Filed With SEC on December 20, 2013)

Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. (Filed With SEC on December 20, 2013)

BIODEL INC. Common Stock, par value $0.01 per share Underwriting Agreement (Filed With SEC on June 20, 2013)

BIODEL INC. Common Stock (par value $0.01 per share) (Filed With SEC on May 13, 2013)

LICENSE AGREEMENT between BIODEL, INC. and AEGIS THERAPEUTICS, LLC June 8, 2012 (Filed With SEC on August 14, 2012)

CERTIFICATE OF DESIGNATION OF SERIES B CONVERTIBLE PREFERRED STOCK OF BIODEL INC. PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW (Filed With SEC on June 27, 2012)

CERTIFICATE OF DESIGNATION OF SERIES B CONVERTIBLE PREFERRED STOCK OF BIODEL INC. PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW (Filed With SEC on June 22, 2012)

BIODEL INC. WARRANT TOPURCHASE COMMON STOCK (Filed With SEC on June 22, 2012)

FORM OF SECURITIES PURCHASE AGREEMENT (Filed With SEC on June 22, 2012)

BASE SALARIES OF NAMED EXECUTIVEOFFICERS OF THE REGISTRANT (Filed With SEC on December 15, 2011)

SUMMARY OF THE REGISTRANT’SNON-EMPLOYEE DIRECTOR COMPENSATION (Filed With SEC on December 15, 2011)

AMENDMENT TO: SUPPLY AGREEMENT BY AND BETWEEN N.V. ORGANON AND BIODEL DATED 4 APRIL 2005 (Filed With SEC on December 15, 2011)

PLACEMENT AGENCY AGREEMENT (Filed With SEC on May 19, 2011)

CERTIFICATE OF DESIGNATION (Filed With SEC on May 19, 2011)

PLACEMENT AGENCY AGREEMENT (Filed With SEC on May 13, 2011)

CERTIFICATE OF DESIGNATION (Filed With SEC on May 13, 2011)

BIODEL INC. (Filed With SEC on May 13, 2011)

SUBSCRIPTION AGREEMENT (Filed With SEC on May 13, 2011)

BASESALARIES OF NAMED EXECUTIVE OFFICERS OF THE REGISTRANT (Filed With SEC on December 14, 2010)

SUMMARY OF THE REGISTRANTS NON-EMPLOYEE DIRECTOR COMPENSATION (Filed With SEC on December 14, 2010)

The following exhibits are filed with this report on Form 8-K (Filed With SEC on October 6, 2010)

The following exhibits are filed with this report on Form 8-K (Filed With SEC on August 25, 2010)

Cash and cash equivalents (Filed With SEC on May 7, 2010)

BIODEL INC. EXECUTIVE EMPLOYMENT AGREEMENT (Filed With SEC on April 1, 2010)

BIODEL INC. (Filed With SEC on April 1, 2010)

Cash and cash equivalents (Filed With SEC on February 5, 2010)

our ability to secure approval by the U.S. Food and Drug Administration, or FDA, for our product candidates under Section 505(b)(2) of the Federal Food, Drug and Cosmetic Act, or... (Filed With SEC on December 14, 2009)

Cash and cash equivalents (Filed With SEC on May 8, 2009)

BIODEL INC. (Filed With SEC on January 7, 2009)

EMPLOYMENT AGREEMENT (Filed With SEC on January 7, 2009)

EX-10.19: BASE SALARIES OF EXECUTIVE OFFICERS (Filed With SEC on December 11, 2008)

EX-10.20: SUMMARY OF THE COMPANY'S NON-EMPLOYEE DIRECTOR COMPENSATION (Filed With SEC on December 11, 2008)

EX-10.3: SUPPLY AGREEMENT (Filed With SEC on August 11, 2008)

- 2 - (Filed With SEC on June 11, 2008)

EX-1.1: FORM OF UNDERWRITING AGREEMENT (Filed With SEC on January 31, 2008)

EX-10.19: FORM OF INCENTIVE STOCK OPTION AGREEMENT (Filed With SEC on December 21, 2007)

EX-10.20: FORM OF OPTION AGREEMENT (Filed With SEC on December 21, 2007)

EX-10.21: EXECUTIVE OFFICER COMPENSATION SUMMARY (Filed With SEC on December 21, 2007)

EX-10.22: NON-EMPLOYEE DIRECTOR COMPENSATION SUMMARY (Filed With SEC on December 21, 2007)

EMPLOYMENT AGREEMENT (Filed With SEC on November 21, 2007)

CONSULTING AGREEMENT (Filed With SEC on November 14, 2007)

SEVERANCE AGREEMENT (Filed With SEC on November 14, 2007)

6Christopher Columbus Avenue Danbury, CT 06810 Phone: (203) 798-3600 Fax: (203) 798-3601 (Filed With SEC on November 14, 2007)

W I T N E S S E T H: (Filed With SEC on October 4, 2007)

COMMERCIAL LEASE (Filed With SEC on July 27, 2007)

4 Christopher Columbus Avenue Danbury, CT ###-###-#### ###-###-#### Mulvaney PROPERTIES Fax ###-###-#### www.mulvaneyproperties.com (Filed With SEC on July 27, 2007)

5,000,000 SHARES BIODEL INC. COMMON STOCK, $0.01 PAR VALUE PER SHARE UNDERWRITING AGREEMENT _________ __, 2007 (Filed With SEC on May 8, 2007)

EX-10.6: AMENDED AND RESTATED EMPLOYMENT AGREEMENT (Filed With SEC on April 26, 2007)

EX-10.7: AMENDED AND RESTATED EMPLOYMENT AGREEMENT (Filed With SEC on April 26, 2007)

EX-10.8: AMENDED AND RESTATED EMPLOYMENT AGREEMENT (Filed With SEC on April 26, 2007)

EX-10.10: SUPPLY AGREEMENT (Filed With SEC on April 26, 2007)

EX-4.1: SPECIMEN STOCK CERTIFICATE (Filed With SEC on March 27, 2007)

EX-10.3: AMENDED AND RESTATED STOCK INCENTIVE PLAN (Filed With SEC on March 27, 2007)

EX-10.4: EMPLOYEE STOCK PURCHASE PLAN (Filed With SEC on March 27, 2007)

EX-10.5: NON-EMPLOYEE DIRECTORS' STOCK OPTION PLAN (Filed With SEC on March 27, 2007)

EX-10.6: AMENDED AND RESTATED EMPLOYMENT AGREEMENT (Filed With SEC on March 27, 2007)

EX-10.7: AMENDED AND RESTATED EMPLOYMENT AGREEMENT (Filed With SEC on March 27, 2007)

EX-10.8: AMENDED AND RESTATED EMPLOYMENT AGREEMENT (Filed With SEC on March 27, 2007)

EX-10.10: SUPPLY AGREEMENT (Filed With SEC on March 27, 2007)

EX-10.11: MANUFACTURING AGREEMENT (Filed With SEC on March 27, 2007)

EX-10.14: LEASE AGREEMENT (Filed With SEC on March 27, 2007)

EX-10.15: LEASE AGREEMENT (Filed With SEC on March 27, 2007)

EX-4.2: FORM OF WARRANT (Filed With SEC on February 7, 2007)

EX-4.3: FORM OF WARRANT (Filed With SEC on February 7, 2007)

EX-4.4: FORM OF WARRANT (Filed With SEC on February 7, 2007)

EX-4.5: FORM OF WARRANT (Filed With SEC on February 7, 2007)

EX-4.6: FORM OF WARRANT (Filed With SEC on February 7, 2007)

EX-4.7: FORM OF SUBSCRIPTION AND RIGHTS AGREEMENT (Filed With SEC on February 7, 2007)

EX-4.8: AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT (Filed With SEC on February 7, 2007)

EX-10.1: FORM OF INDEMNITY AGREEMENNT (Filed With SEC on February 7, 2007)

EX-10.2: 2004 STOCK INCENTIVE PLAN (Filed With SEC on February 7, 2007)

EX-10.6: EMPLOYMENT AGREEMENT (Filed With SEC on February 7, 2007)

EX-10.7: EMPLOYMENT AGREEMENT (Filed With SEC on February 7, 2007)

EX-10.8: EMPLOYMENT AGREEMENT (Filed With SEC on February 7, 2007)

EX-10.9: CONSULTING AGREEMENT (Filed With SEC on February 7, 2007)

EX-10.12: CHANGE OF CONTROL AGREEMENT (Filed With SEC on February 7, 2007)

EX-10.13: EXECUTIVE SEVERANCE AGREEMENT (Filed With SEC on February 7, 2007)

Category

Industry

Companies

Contracts

ALBIREO PHARMA, INC. Contracts & Agreements